These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 36814327)

  • 41. Correlation between SACE (Subjective Angiographic Chemoembolization Endpoint) score and tumor response and its impact on survival after DEB-TACE in patients with hepatocellular carcinoma.
    Habbel VSA; Zeile M; Stavrou GA; Wacker F; Brüning R; Oldhafer KJ; Rodt T
    Abdom Radiol (NY); 2019 Oct; 44(10):3463-3479. PubMed ID: 31332502
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Dhondt E; Lambert B; Hermie L; Huyck L; Vanlangenhove P; Geerts A; Verhelst X; Aerts M; Vanlander A; Berrevoet F; Troisi RI; Van Vlierberghe H; Defreyne L
    Radiology; 2022 Jun; 303(3):699-710. PubMed ID: 35258371
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety.
    Li H; Wu F; Duan M; Zhang G
    Medicine (Baltimore); 2019 May; 98(21):e15314. PubMed ID: 31124925
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis of six randomized controlled trials.
    Wang H; Cao C; Wei X; Shen K; Shu Y; Wan X; Sun J; Ren X; Dong Y; Liu Y; Zhai B
    J Cancer Res Ther; 2020; 16(2):243-249. PubMed ID: 32474508
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
    Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
    J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.
    Megías Vericat JE; García Marcos R; López Briz E; Gómez Muñoz F; Ramos Ruiz J; Martínez Rodrigo JJ; Poveda Andrés JL
    Radiologia; 2015; 57(6):496-504. PubMed ID: 25857250
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The safety and efficacy of oxaliplatin-loaded drug-eluting beads transarterial chemoembolization for the treatment of unresectable or advanced lung cancer.
    Bi Y; Li F; Ren J; Han X
    Front Pharmacol; 2022; 13():1079707. PubMed ID: 36518678
    [No Abstract]   [Full Text] [Related]  

  • 48. Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis.
    Bargellini I; Lorenzoni V; Lorenzoni G; Scalise P; Andreozzi G; Bozzi E; Giorgi L; Cervelli R; Scandiffio R; Perrone O; Meccia DV; Boccuzzi A; Daviddi F; Cicorelli A; Lunardi A; Crocetti L; Turchetti G; Cioni R
    Eur Radiol; 2021 Oct; 31(10):7512-7522. PubMed ID: 33871708
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients.
    Song MJ; Park CH; Kim JD; Kim HY; Bae SH; Choi JY; Yoon SK; Chun HJ; Choi BG; Lee HG
    Eur J Gastroenterol Hepatol; 2011 Jun; 23(6):521-7. PubMed ID: 21537127
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Super-selective transarterial chemoembolization of hepatocellular carcinoma with doxorubicin-eluting beads sized 40-75 microns: assessment of efficacy and safety.
    Ballı HT; Aikimbaev K
    Diagn Interv Radiol; 2020 Sep; 26(5):482-487. PubMed ID: 32815520
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The development of early ascites is associated with shorter overall survival in patients with hepatocellular carcinoma treated with drug-eluting embolic chemoembolization.
    Pipa-Muñiz M; Sanmartino S; Mesa A; Álvarez-Navascués C; González-Diéguez ML; Cadahía V; Rodríguez JE; Vega F; Rodríguez M; Costilla-García SM; Varela M
    BMC Gastroenterol; 2020 Jun; 20(1):166. PubMed ID: 32487071
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative Study of Drug-eluting Beads versus Conventional Transarterial Chemoembolization for Treating Peculiar Anatomical Sites of Gastric Cancer Liver Metastasis.
    Xu H; Min X; Ren Y; Yang L; Liu F
    Med Sci Monit; 2020 May; 26():e922988. PubMed ID: 32474569
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Systematic Review and Pharmacokinetic Meta-analysis of Doxorubicin Exposure in Transcatheter Arterial Chemoembolization and Doxorubicin-Eluted Beads Chemoembolization for Treatment of Unresectable Hepatocellular Carcinoma.
    Zarisfi M; Kasaeian A; Wen A; Liapi E
    Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):449-466. PubMed ID: 35543895
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
    Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
    Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy, safety, and prognostic factors of drug-eluting beads transarterial chemoembolization using CalliSpheres in treating huge hepatocellular carcinoma patients.
    Wang Z; Mu K; Lv Y; Zhao L; Li B; Hao Y; Wang N
    Ir J Med Sci; 2022 Dec; 191(6):2493-2499. PubMed ID: 35064533
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40-µm doxorubicin-eluting microspheres.
    Albrecht KC; Aschenbach R; Diamantis I; Eckardt N; Teichgräber U
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):23-32. PubMed ID: 32880029
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Survival, tumour response and safety of 70-150 μm versus 100-300 μm doxorubicin drug-eluting beads in transarterial chemoembolisation for hepatocellular carcinoma.
    Huo YR; Xiang H; Chan MV; Chan C
    J Med Imaging Radiat Oncol; 2019 Dec; 63(6):802-811. PubMed ID: 31709778
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transarterial chemoembolization with doxorubicin-loaded beads for inoperable or recurrent colorectal cancer.
    Bi Y; Shi X; Ren J; Yi M; Han X; Song M
    Abdom Radiol (NY); 2021 Jun; 46(6):2833-2838. PubMed ID: 33386908
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug-eluting bead transarterial chemoembolization with medium-sized versus small-sized CalliSpheres microspheres in unresectable primary liver cancer.
    Zhang J; Feng GA; Li Y; Wang W
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):388-393. PubMed ID: 34708554
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A multi-institutional study to predict the benefits of DEB-TACE and molecular targeted agent sequential therapy in unresectable hepatocellular carcinoma using a radiological-clinical nomogram.
    Liu K; Zheng X; Lu D; Tan Y; Hou C; Dai J; Shi W; Jiang B; Yao Y; Lu Y; Cao Q; Chen R; Zhang W; Xie J; Chen L; Jiang M; Zhang Z; Liu L; Liu J; Li J; Lv W; Wu X
    Radiol Med; 2024 Jan; 129(1):14-28. PubMed ID: 37863847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.